TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven prostate adenocarcinoma.~* Planned prostatectomy with lymph node dissection.~* Intermediate to high-risk disease (as determined by elevated Prostate-specific antigen (PSA) \[PSA\>10\], T-stage \[T2b or greater\], Gleason score \[Gleason score \> 6\] or other risk factors).~* Diagnostic CT or MRI as part of the PET study or performed within one month of PSMA PET.~* Karnofsky performance status of greater than 50 (or Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) equivalent).~* Age \> 18.~* Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam.~* Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy.~* Including focal ablation techniques (HiFu).~* Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging and surgery.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68 labeled PSMA-11 PET (Type: EXPERIMENTAL): PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~Male or female age ≥ 18 years with histologically confirmed diagnosis of melanoma and unresected stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c regardless of prior line of therapy. Subject is candidate for intralesional therapy administration into cutaneous, subcutaneous, or nodal disease and must also have measurable disease, serum lactate dehydrogenase ≤ 1.5 x upper limit of normal, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate hematologic, hepatic, and renal organ function.~Key Exclusion Criteria:~Subject must not have clinically active cerebral metastases, greater than 3 visceral metastases (this does not include lung metastases or any nodal metastases associated with visceral organs) or any bone metastases melanoma, primary ocular or mucosal melanoma, history or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or symptomatic autoimmune disease, or evidence of immunosuppression for any reason. Subject known to have acute or chronic active hepatitis B or hepatitis C infection, or human immunodeficiency virus infection will also be excluded. Subject who has active herpetic skin lesions or prior complications of herpes simplex virus type 1 ( HSV-1) infection (eg, herpetic keratitis or encephalitis), and/or requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use will also be excuded. Subject must not have received previous treatment with talimogene laherparepvec.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Talimogene Laherparepvec (Type: EXPERIMENTAL): Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who are at least 6 years of age, and who will not have reached their 13th birthday~* Diagnosis of ADHD~* Normal intelligence~* Able to swallow capsules~Exclusion Criteria:~* Weight less than 20 kg or more than 60 kg at study entry~* Prior treatment with atomoxetine~* History of seizure disorder, suicidal risk, alcohol or drug abuse within the past 3 months~* History of severe allergies or multiple adverse drug reactions~* Cardiovascular disorders: hypertension, unexplained cardiac signs or symptoms, QT prolongation, inherited cardiac disorders

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): 0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of FBF001

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject between 21-40 years old~* with body mass index in the range 18 to 30 Kg/m2~Exclusion Criteria:~* Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, osteo-muscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness~* Any vaccination within three months before the inclusion~* Any vaccination against H5N1 virus~* Planned receipt of any vaccine during the study~* Any infectious disease within the month before the inclusion~* Any history of animal proteins allergy, animal allergy and/or any drug, food and pollen allergy~* Who has received blood or plasma derivatives (human or animal) in the three months preceding the initiation of the study~* Any medication within 14 days before the inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of that drug

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- FBF001 (Type: EXPERIMENTAL): FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.~FBF001 is administered once during 1 day or once per day during 5 days.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females over the age of 40~* Scheduled to undergo pneumonectomy or lobectomy~Exclusion Criteria:~* History (hx) of atrial fibrillation~* Prior severe side effects from amiodarone~* Elevated liver enzymes \>3 times the upper limit of normal (UNL)~* QTc interval \> 450 ms~* Receiving class Ia or class III antiarrhythmics

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amiodarone (Type: EXPERIMENTAL): Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
- No treatment (Type: NO_INTERVENTION): Patients in this group receive no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age over 18 years old, clinically diagnosed as acute ischemic stroke;~2. in accordance with the indications for intravenous thrombolysis;~3. The patient or family member signs an informed consent form.~Exclusion Criteria:~1. Patients with transient ischemic attack;~2. Imaging examination of patients with cerebral hemorrhage~3. patients with cerebral arteritis~4. ALT, AST ≥ 3 times the upper limit of normal value, Cr ≥ 1.5 times the upper limit of normal value~5. There is a tendency to bleed, and severe bleeding has occurred within 3 months~6. Patients with ginkgo drugs, alcohol, glycerol allergies or allergies~7. Patients with pregnancy plans, pregnancy and breastfeeding~8. Patients who participated in other drug clinical studies in the past month~9. Patients considered by the investigator to be unfit to participate in the clinical study (eg, mental, abnormal, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ginkgolide group (Type: EXPERIMENTAL): ginkgolide plus alteplase
- control (Type: NO_INTERVENTION): alteplase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Supplement of a Standardised Bilberry Extract Modifies Glycaemic Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects~* Aged \>40 and \<70~* Clinical diagnosis of Type 2 diabetes controlling their diabetes by diet alone~* All subjects must live in the Aberdeenshire area of Scotland~Exclusion Criteria:~* Medical exclusion criteria~* Clinical diagnosis of thromboembolic or coagulation disease~* Clinical diagnosis of unregulated thyroid disease~* Clinical diagnosis of kidney disease~* Clinical diagnosis of severe gastrointestinal disorders~* History of Alcohol or any other substance abuse

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bilberry capsule first, then control cap (Type: EXPERIMENTAL): Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)
- Control capsule first, then bilberry cap (Type: EXPERIMENTAL): Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give written informed consent and authorize Health Insurance Portability and Accountability Act (HIPAA).~* Completed COL MIG-301 or COL MIG-302 within the last 12 weeks. Subjects that completed COL MIG-301 prior to COL MIG-305 being available will be allowed to enroll as long as enrollment occurs within 4 weeks of COL MIG-305 activation at their site. (NOTE: Additional subjects may qualify if they completed COL MIG-301 or COL MIG-302 \>12 weeks prior or if they have not participated in either prior study, but meet eligibility criteria outlined for COL MIG-302.)~* Females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner).~* Able and willing to complete an electronic diary to record details of all migraine attacks treated with study drug.~Exclusion Criteria:~* Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the subject unsuitable for the study.~* Pregnant or breast-feeding women.~* Women of child-bearing potential not using or not willing to use highly effective contraception.~* Participant is at imminent risk of suicide (positive response to question 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).~* Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes since completing COL MIG-301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174).~* Participation in any clinical trial of an experimental drug or device since completing EoS/Visit 2 of COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lasmiditan 100mg (Type: EXPERIMENTAL): Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
- Lasmiditan 200mg (Type: EXPERIMENTAL): Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Moderate-to-severe rosacea (as per the IGA score) on the proposed facial treatment area consisting of:~   1. At least 15 and not more than 75 facial papules and pustules, excluding lesions involving the eyes and scalp;~  2. No more than 2 nodules on the face.~2. Presence of or history of erythema and/or flushing on the face.~Exclusion Criteria:~1. Presence of any skin condition and/or Excessive facial hair, on the face that would interfere with the diagnosis or assessment of rosacea.~2. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe), or plaque-like facial edema.~3. History of hypersensitivity or allergy to minocycline, any other tetracycline, or of any other component of the formulation.~4. Active ocular rosacea (eg, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX103 1.5% (Type: EXPERIMENTAL): Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
- Vehicle foam (Type: PLACEBO_COMPARATOR): Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemia (serum urate ≥8.0 mg/dL and gout by American Rheumatism Association Criteria~* Renal function defined as a serum creatinine level of \< 2.0 mg/dL and creatinine clearance of \> 20 milliliters per minute (mL/min) by Cockroft and Gault formula.~Exclusion Criteria:~* History of xanthinuria~* Intolerance to allopurinol~* Presence of renal calculi,~* Alcohol intake of ≥ 14 drinks/week~* Clinically significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 240 mg QD (Type: EXPERIMENTAL): None
- Allopurinol QD (Type: ACTIVE_COMPARATOR): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~  * No other pancreatic tumor type, including either of the following:~    * Neuroendocrine tumor~   * Acinar cell tumor~ * Metastatic disease~* Measurable disease in an area not previously irradiated~* No cerebral metastases or meningeal involvement of the tumor~PATIENT CHARACTERISTICS:~Age~* 18 to 75~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (biliary drainage allowed)~Renal~* Creatinine \< 120 mmol/L~Cardiovascular~* No prior myocardial infarction~* No prior angina~* No uncompensated cardiac or coronary insufficiency~* No symptomatic arrhythmia~Gastrointestinal~* No prior inflammatory bowel disease~* No prior chronic diarrhea~* No unresolved symptomatic occlusion or subocclusion of the bowel~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No ongoing active infection~* No other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No contraindication to study treatment~* No other serious medical disorder that would preclude study treatment~* No psychiatric disorder or social or geographic situation that would preclude study participation~* Not detained or under the guardianship of another person~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* No concurrent participation in another clinical trial using therapeutic experimental agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Folfirinox (Type: EXPERIMENTAL): None
- Gemcitabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age;~* laboratory or clinical-epidemiological confirmation of COVID-19 (history of close or home contact with a laboratory-confirmed case who has fever or at least one of the respiratory signs or symptoms, in the last 14 days after contact, and for which it was not possible to carry out the specific laboratory investigation)~Exclusion Criteria:~* Immunosuppressed patients of any kind;~* Pregnant women;~* More than 14 days from the onset of symptoms;~* Not accept participation or non-signature of the IC;~* Undiagnosed cases, suspected or probable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCG vaccine (Type: ACTIVE_COMPARATOR): BCG Group (n = 200): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group (n = 200): 0.9% saline solution in the same volume as BCG vaccine in a single dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete